Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T18:22:34.157Z.
Calculation as of: 2026-10-06T18:22:34.157Z.
Quote observation: 2026-10-06T18:15:41.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f9e30a8d320e3cb26c3b838953cbb8bfe3908fe2cbbcdc0c218fd5db8a33f332
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Pulsenmore Ltd. Ordinary Shares
Market Cap
$14.44M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$14.92M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$13.93M
Price/OCF Ratio
26.56
TTM Avg
28.16
3Y Avg
28.16
5Y Avg
28.16
Market Cap
$15.11M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$15.24M
Price/OCF Ratio
N/A
TTM Avg
57.00
3Y Avg
57.00
5Y Avg
57.00
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Pulsenmore Ltd. Ordinary Shares (PLSM) | $14.44M | N/A | N/A | N/A | N/A |
| Obsidian Therapeutics Inc. (OBX)vs › | $14.01M | N/A | N/A | N/A | N/A |
| Pasithea Therapeutics Corp. (KTTA)vs › | $14.92M | N/A | N/A | N/A | N/A |
| Vyome Holdings, Inc. (HIND)vs › | $13.93M | 26.56 | 28.16 | 28.16 | 28.16 |
| Sintx Technologies, Inc. (SINT)vs › | $13.78M | N/A | N/A | N/A | N/A |
| Jin Medical International Ltd. (ZJYL)vs › | $15.11M | N/A | N/A | N/A | N/A |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.24M | N/A | 57.00 | 57.00 | 57.00 |
| Optimi Health Corp. (OPTH)vs › | $13.48M | N/A | N/A | N/A | N/A |
| Passage Bio, Inc. (PASG)vs › | $13.40M | N/A | N/A | N/A | N/A |
| IN8bio, Inc. (INAB)vs › | $13.33M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
